Traws Pharma, Inc. SEC Filings

Traws Pharma, Inc. describes its ability to sell shares of common stock under an existing at-the-market equity offering program. Under a new prospectus supplement dated July 10, 2026, the company may offer and sell shares with an aggregate offering price of up to $5,575,709 through Citizens JMP Securities, LLC, reflecting its current “baby shelf” limitation under General Instruction I.B.6 of Form S-3. This activity is conducted pursuant to an at-the-market offering agreement that permits sales of up to $50,000,000 in total and relies on an effective shelf registration statement on Form S-3 declared effective on July 9, 2026.

Traws Pharma, Inc. is activating an at-the-market equity program under an existing shelf registration, allowing it to sell up to $5,575,709 of common stock through Citizens JMP Securities on a discretionary, from‑time‑to‑time basis. Shares may be sold on Nasdaq under the symbol TRAW or via other permitted methods, with Citizens earning a 3.0% commission on gross proceeds and being deemed an underwriter.

The company’s broader shelf capacity is $139,185,641.25, but this supplement covers only the ATM tranche. As of June 30, 2026, it had 15,228,328 shares outstanding, and illustrative math assumes selling 7,965,299 shares at $0.70, bringing total shares to 23,193,627, though actual sales and prices may differ. Proceeds are expected to support clinical and preclinical programs, other R&D, and general corporate purposes.

The company reports an accumulated deficit of $647.1 million and cash of about $5.0 million, and discloses substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027 without additional funding. It also highlights Nasdaq listing-compliance history, dilution risk from this and future financings, and its status as a smaller reporting company with reduced disclosure requirements.

Traws Pharma, Inc. reported the results of its 2026 annual stockholder meeting and related governance approvals. Stockholders approved an amendment to the 2021 Incentive Compensation Plan that increases the shares available for equity awards by 2,000,000, effective July 8, 2026. They also re-elected seven directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, and approved the issuance of common shares upon exercise of Series B and Series C warrants issued under an April 15, 2026 Securities Purchase Agreement, as required by Nasdaq Listing Rule 5635(d). A proposal to permit adjournment of the meeting, if needed, was approved but not used because all key proposals passed.

Traws Pharma, Inc. files a registration statement on Form S-3 to register up to $139,185,641.25 of unsold securities pursuant to Rule 415(a)(6). The filing replaces the company’s prior registration statement and covers offers of common stock, preferred stock, debt securities, warrants and units, to be sold from time to time.

The prospectus states the aggregate offering price limit of $139,185,641.25, describes permitted distribution methods, and notes incorporated reports (including the 2025 Form 10-K). The audit report for 2025 includes a going-concern explanatory paragraph.

Traws Pharma, Inc. is preparing an updated toxicology data package for tivoxavir marboxil to address information requests from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The company expects to resubmit this package in the third quarter of 2026 to allow a planned Phase 2a human influenza challenge study in healthy volunteers to proceed.

Management believes the study could provide important proof-of-concept data for tivoxavir marboxil as an oral prophylaxis for seasonal influenza. Traws notes that tivoxavir marboxil has shown broad in vitro activity across multiple seasonal influenza strains and a pharmacokinetic profile consistent with chemoprophylactic use, and it plans to profile additional molecules in its influenza treatment program.

Traws Pharma, Inc. reported that its planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred after a negative review by the UK Medicines and Healthcare Products Regulatory Agency. This pushes back clinical evaluation of its lead long-acting influenza antiviral in humans.

The company emphasizes that TXM previously showed potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile suited for bird flu treatment and prevention. Management stresses that influenza antivirals remain a high priority and notes a cash runway extending to Q1 2027 as it advances backup influenza candidates with similar antiviral and pharmacokinetic characteristics but designed to avoid potential regulatory concerns.

Traws Pharma, Inc. is asking stockholders to vote on key governance and equity proposals at its 2026 virtual annual meeting on July 8, 2026. Holders of 15,150,669 common shares as of May 18, 2026 can participate and vote online.

Stockholders will elect seven directors and consider amending the 2021 Incentive Compensation Plan to add 2,000,000 shares for future equity awards and make administrative updates. They are also asked to ratify KPMG LLP as auditor, approve share issuance upon exercise of Series B and Series C warrants under Nasdaq Listing Rule 5635(d), and authorize potential adjournment to gather additional votes.